KMDA vs MCK vs VALN Stock Comparison

Kamada, Mckesson and Valneva SE Prices as of Oct 28, 2026 Peers: Industry group
1 more company in this comparison (VRTX) Create a free account to keep reading and compare up to 10 companies.
KMDA Kamada Ltd
$8.00 -7.2% 1M +15.1% 1Y
Market cap
$457.71M
P/E
20.7x
Revenue (TTM)
$191.85M
Div. yield
0.06%
Biotechnology Healthcare
7 wins
MCK Mckesson Corp
$960.80 +12.2% 1M +19.4% 1Y
Market cap
$116.14B
P/E
25.3x
Revenue (TTM)
$410.98B
Div. yield
0.00%
Drug Distribution Healthcare
5 wins
VALN Valneva SE
$5.74 -11.3% 1M -37.1% 1Y
Market cap
$475.11M
P/E
–
Revenue (TTM)
$166.68M
Div. yield
–
Biotechnology Healthcare

Head to Head

12 decided of 12

Kamada leads on 7 of the 12 questions below (Kamada 7, Mckesson 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionKMDAMCKVALNLeader
Larger companyMarket capitalisation $457.71M $116.14B $475.11M MCK
Cheaper on earningsLower P/E, profitable companies only 20.7x 25.3x -3.5x KMDA
Cheaper on forward earningsLower price / next fiscal year consensus EPS 16.0x 20.4x — KMDA
Faster revenue growthRevenue growth, trailing twelve months +13.2% +8.8% -21.9% KMDA
More profitableNet margin, trailing twelve months 11.5% 1.1% -80.6% KMDA
Better return on capitalReturn on invested capital 10.2% 107.9% -44.8% MCK
Less leveragedLower net debt / EBITDA -1.5x 0.6x — KMDA
Higher dividend yieldTrailing dividend yield 0.06% 0.00% 0.00% KMDA
Better 1-year returnPrice return, last 12 months +15.1% +19.4% -37.1% MCK
Better 5-year returnAnnualised price return, 5 years +7.0%/yr +35.8%/yr -33.7%/yr MCK
Less volatileAnnualised volatility, 1 year 34.7% 30.7% 70.9% MCK
Higher overall scoreMean of the five percentile scores vs peers 84/100 58/100 34/100 KMDA

Percentile Scorecard

KMDAMCKVALN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisKMDAMCKVALN
Valuation 97 #21 of 625 50 #13 of 25 55 #281 of 625
Growth 71 #177 of 602 65 #9 of 24 8 #553 of 602
Profitability 87 #70 of 549 65 #9 of 24 52 #262 of 549
Financial Health 74 #168 of 654 48 #14 of 26 21 #514 of 654
Shareholder Returns 90 #38 of 367 60 #7 of 16 33 #245 of 367
Overall 84 58 34
  • KMDA ranked among 672 companies in Pharmaceuticals and Biotechnology
  • MCK ranked among 27 companies in Healthcare Payers and Distributors
  • VALN ranked among 672 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodKMDAMCKVALNSPY
1 month -7.2%+12.2%-11.3% +0.9%
3 months +14.1%+8.1%+13.2% +5.9%
6 months -1.4%+16.8%+7.7% +8.5%
Year to date +13.3%+17.1%-34.9% +13.3%
1 year +15.1%+19.4%-37.1% +12.4%
3 years +93.2%+114.4%-46.9% +88.1%
3 years, per year +24.6%+29.0%-19.0% +23.5%
5 years +40.1%+362.2%-87.1% +68.2%
5 years, per year +7.0%+35.8%-33.7% +11.0%
10 years +34.5%+674.2%— +263.4%
10 years, per year +3.0%+22.7%— +13.8%

Risk

MeasureKMDAMCKVALNSPY
Volatility, 1Y 34.7%30.7%70.9% 12.7%
Downside volatility, 1Y 33.2%27.4%79.0% 12.7%
Beta vs S&P 500, 1Y 1.01-0.270.53 1.00
Return / volatility, 1Y 0.440.63-0.52 0.98
Max drawdown, 5Y -44.4%-27.2%-94.5% -25.4%
From 52-week high -14.1%-6.7%-52.1% -0.9%
52-week high $9.31$1,030.18$11.99 $779.14
52-week low $6.62$725.17$4.78 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleKMDAMCKVALN
P/E now vs peer median 20.9xmedian 17.4x 24.8xmedian 23.9x -3.6xmedian 17.4x
P/S now vs peer median 2.4xmedian 9.1x 0.3xmedian 0.3x 3.0xmedian 9.1x
EV/EBITDA now vs peer median 9.2xmedian 17.1x 16.1xmedian 12.7x —median 17.1x
P/FCF now vs peer median 17.5xmedian 19.0x 17.5xmedian 15.4x -7.4xmedian 19.0x
P/B now vs peer median 1.7xmedian 2.2x -26.4xmedian 2.5x 5.4xmedian 2.2x
PEG now vs peer median 0.30median 0.34 2.08median 1.34 0.01median 0.34

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsKMDAMCKVALN
Revenue $191.85M $410.98B $166.68M
Gross profit $78.31M $14.96B $27.35M
Operating income $27.83M $6.50B -$134.30M
Net income $22.25M $5.30B -$183.90M
Free cash flow $26.32M $6.42B -$67.63M
R&D $9.91M – $96.94M
EPS (diluted) $0.38 $38.52 $-1.60
Cash & equivalents $29.47M $5.16B $138.81M
Total debt $74.86M $9.73B $210.28M
Shares (diluted) 58.35M 119.20M 84.09M
Enterprise value $166.77M $100.04B -$81.45M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricKMDAMCKVALN
P/E 20.9x 24.8x -3.6x
P/FCF 17.5x 17.5x -7.4x
P/Operating cash flow 12.9x 16.3x -7.7x
P/S 2.4x 0.3x 3.0x
P/B 1.7x -26.4x 5.4x
P/Tangible book 1.7x -13.6x 7.2x
EV/EBITDA 9.2x 16.1x –
EV/EBIT 14.3x 18.0x -4.2x
EV/Revenue 2.1x 0.3x 3.4x
EV/FCF 15.1x 18.2x -8.4x
EV/Operating cash flow 11.1x 17.0x -8.8x
PEG (3Y EPS CAGR) 0.30 2.08 0.01

Growth

14 metrics
MetricKMDAMCKVALN
Revenue growth (1Y) 13.2% 8.8% -21.9%
Revenue CAGR (3Y) 9.6% 13.1% -22.0%
Gross profit growth (1Y) 5.9% 11.2% -73.8%
Gross profit CAGR (3Y) 12.9% 6.6% -41.6%
Operating income growth (1Y) 10.3% 46.6% -146.1%
Operating income CAGR (3Y) 43.1% 13.5% -379.4%
Net income growth (1Y) 17.0% 58.1% -153.7%
Net income CAGR (3Y) 258.5% 10.7% -164.3%
EPS growth (1Y) 14.5% 52.8% -113.2%
EPS CAGR (3Y) 70.4% 12.0% -322.9%
Operating cash flow growth (1Y) -10.9% 4.7% -396.6%
Operating cash flow CAGR (3Y) 5.6% 10.7% 33.2%
Free cash flow growth (1Y) -16.7% 6.8% -154.4%
Free cash flow CAGR (3Y) 1.0% 11.3% 34.4%

Profitability

14 metrics
MetricKMDAMCKVALN
Gross margin 40.8% 3.6% 16.4%
EBITDA margin 22.5% 1.8% –
Operating margin 14.5% 1.6% -80.6%
Pretax margin 13.9% 1.6% -110.3%
Net margin 11.5% 1.1% -80.6%
FCF margin 13.7% 1.6% -40.6%
Operating cash flow margin 18.6% 1.7% -38.9%
Return on equity 8.4% – -203.7%
Return on assets 5.8% 6.2% -42.3%
Return on invested capital 10.2% 107.9% -44.8%
Return on capital employed 8.3% 43.4% -42.4%
Asset turnover 0.5x 4.8x 0.4x
Cash conversion (OCF / net income) 1.6x 1.3x 0.4x
Stock comp / revenue 1.1% – –

Financial Health

11 metrics
MetricKMDAMCKVALN
Debt / assets 1.6% 11.0% 47.4%
Debt / equity 0.0x -2.3x 2.3x
Net debt / EBITDA -1.5x 0.6x –
Debt / FCF 0.2x 1.5x -3.1x
Liabilities / assets 29.6% 104.8% 79.1%
Equity / assets 70.4% -4.8% 20.9%
Interest coverage 93.7x 23.6x -2.8x
Current ratio 4.1x 0.9x 2.2x
Quick ratio 2.3x 0.5x 1.3x
Cash ratio 1.4x 0.1x 1.2x
Altman Z-score 3.58 5.88 -1.85

Shareholder Returns

7 metrics
MetricKMDAMCKVALN
Dividend yield 5.3% 0.4% –
Net buyback yield 0.0% 5.9% -10.6%
Shareholder yield 5.2% 6.3% -10.6%
Payout ratio (earnings) 129.6% 7.4% –
Payout ratio (FCF) 109.6% 6.1% –
Dividend growth (1Y) – 11.3% –
Dividend CAGR (3Y) – 10.0% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusKMDAMCKVALN
Forward P/E 16.0xFY2026 20.4xFY2026 –
EPS, next fiscal year $0.50FY2026 $47.15FY2026 $-0.99FY2026
EPS growth, next FY +38.9%FY2026 +20.6%FY2026 –
EPS growth, the year after +24.0% +11.0% –
Revenue, next fiscal year $209.90MFY2026 $444.47BFY2026 $162.94MFY2026
Revenue growth, next FY +16.3%FY2026 +10.2%FY2026 -19.0%FY2026
Revenue growth, the year after +13.6% +1.5% +96.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersKMDAMCKVALN
Held by institutions 8.6% 89.1% 4.4%
Institutions holding 50 2,010 20
Change in shares held, QoQ -3.1% -0.7% -3.3%
Institutions buying 24 882 13
Institutions selling 18 791 1
Buyers to sellers 1.33 1.12 13.00

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

KMDAMCKVALN
KMDA 1.00 -0.01 0.22
MCK -0.01 1.00 0.03
VALN 0.22 0.03 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, KMDA, MCK and VALN?

Mckesson (MCK) is the largest by market capitalisation: Kamada (KMDA) $457.71M, Mckesson (MCK) $116.14B, Valneva SE (VALN) $475.11M.

Which stock is cheaper, KMDA, MCK and VALN?

Kamada (KMDA) trades on the lowest price-to-earnings ratio (Kamada (KMDA) 20.7x, Mckesson (MCK) 25.3x, Valneva SE (VALN) -3.5x). On next year's consensus earnings, Kamada (KMDA) is cheapest (Kamada (KMDA) 16.0x, Mckesson (MCK) 20.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Kamada (KMDA) grew revenue fastest over the trailing twelve months: Kamada (KMDA) +13.2%, Mckesson (MCK) +8.8%, Valneva SE (VALN) -21.9%.

Which company is more profitable?

Kamada (KMDA) has the highest net margin (Kamada (KMDA) 11.5%, Mckesson (MCK) 1.1%, Valneva SE (VALN) -80.6%). On return on invested capital, Mckesson (MCK) leads (Kamada (KMDA) 10.2%, Mckesson (MCK) 107.9%, Valneva SE (VALN) -44.8%).

Which stock has performed better?

Over the past year Mckesson (MCK) returned the most: Kamada (KMDA) +15.1%, Mckesson (MCK) +19.4%, Valneva SE (VALN) -37.1%. Over five years, Mckesson (MCK) compounded fastest (Kamada (KMDA) +7.0%/yr, Mckesson (MCK) +35.8%/yr, Valneva SE (VALN) -33.7%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Kamada (KMDA) has the highest dividend yield: Kamada (KMDA) 0.06%, Mckesson (MCK) 0.00%, Valneva SE (VALN) 0.00%. Valneva SE (VALN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Mckesson (MCK) has been the steadiest (Kamada (KMDA) 34.7%, Mckesson (MCK) 30.7%, Valneva SE (VALN) 70.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, KMDA, MCK and VALN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Kamada (KMDA) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.